Biology of primary breast cancer in older women treated by surgery: With correlation with long-term clinical outcome and comparison with their younger counterparts

British Journal of Cancer

Volumn 108, Issue 5, 2013, Pages 1042-1051

  Syed, B M ^a   Green, A R ^a   Paish, E C ^a   Soria, D ^a   Garibaldi, J ^a   Morgan, L ^a   Morgan, D A L ^b   Ellis, I O ^a   Cheung, K L ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

biology; breast cancer; clinical outcome; older women

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CYTOKERATIN 14; CYTOKERATIN 17; CYTOKERATIN 18; CYTOKERATIN 19; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ESTROGEN RECEPTOR; KI 67 ANTIGEN; MUCIN 1; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN KINASE LKB1; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; VASCULOTROPIN RECEPTOR;

AGED; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LONG TERM CARE; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84875425312     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.601     Document Type: Article

References (53)

1. Abd El-Rehim D, Ball G, Pinder S, Rakha E, Paish C, Robertson J, Macmillan D, Blamey R, Ellis I (2005) High-throughput protein expression analysis usingtissue microarray technology of a large well-characterised series identifiesbiologically distinct classes of breast cancer confirming recent cDNAexpression analyses. Int J Cancer 116: 340-350.
2. Abd El-Rehim D, Pinder S, Paish C, Bell J, Blamey R, Robertson J, Nicholson R, Ellis I (2004) Expression of luminal and basal cytokeratins in human breastcarcinoma. J Pathol 203 (2) : 661-671.
3. Akhtar S, Allan S, Rodger A, Chetty U, Smyth J, Leonard R (1991) A 10-yearexperience of tamoxifen as primary-treatment of breast-cancer in 100elderly and frail patients. Eur J Surg Oncol 17: 30-35.
4. Aleskandarany M, Rakha E, Macmillan R, Powe D, Ellis I, Green A (2011) MIB1/Ki-67 labelling index can classify grade 2 breast cancer into twoclinically distinct subgroups. Breast Cancer Res Treat 127 (3) : 591-599.
5. Allan SG, Rodger A, Smyth JF, Leonard RC, Chetty U, Forrest AP (1985) Tamoxifen as primary treatment of breast cancer in elderly or frailpatients: a practical management. Br Med J (Clin Res Ed) 290 (6465) : 358.
6. Biganzoli E, Coradini D, Ambrogi F, Garibaldi JM, Lisboa P, Soria D, Green AR, Pedriali M, Piantelli M, Querzoli P, Demicheli R, Boracchi P, Nenci I, Ellis IO, Alberti S (2011) p53 status identifies two subgroups of triplenegativebreast cancers with distinct biological features. Jpn J Clin Oncol41 (2) : 172-179.
7. Callagy G, Pharoah P, Pinder S, Hsu F, Nielsen T, Ragaz J, Ellis I, Huntsman D, Caldas C (2006) Bcl-2 is a prognostic marker in breast cancerindependently of the Nottingham Prognostic Index. Clin Cancer Res 12 (8) :2468-2475.
8. Callagy G, Webber M, Pharoah P, Caldas C (2008) Meta-analysis confirmsBCL2 is an independent prognostic marker in breast cancer. BiomedCentral Cancer 8: 153.
9. Calza S, Hall P, Auer G, Bjöhle J, Klaar S, Kronenwett U, Liu ET, Miller L, Ploner A, Smeds J, Bergh J, Pawitan Y (2006) Intrinsic molecular signatureof breast cancer in a population-based cohort of 412 patients. BreastCancer Res 8 (4) : R34.
10. Camp R, Charette L, Rimm D (2000) Validation of tissue microarraytechnology in breast carcinoma. Lab Invest 80: 1943-1949.
11. Camp R, Dolled-Filhart M, Rimm D (2004) X-tile: a new bio-informatics toolfor biomarker assessment and outcome-based cut-point optimization. ClinCancer Res 10 (21) : 7252-7259.
12. Cheung K, Wong A, Parker H, Li V, Winterbottom L, Morgan D, Ellis I (2008) Pathological features of primary breast cancer in the elderly basedon needle core biopsies-A large series from a single centre. Crit Rev OncolHematol 67: 263-267.
13. Ciatto S, Cirillo A, Confortini M, Cardillo C (1996) Tamoxifen as primarytreatment of breast cancer in elderly patients. Neoplasma 43-45.
14. Daidone M, Coradini D, Martelli G, Veneroni S (2003) Primary breast cancerin elderly women: biological profile and relation with clinical outcome.Crit Rev Oncol Hematol 45: 313-325.
15. Dawson S, Makretsov N, Blows F, Driver K, Provenzano E, Le Quesne J, Baglietto L, Severi G, Giles G, McLean C, Callagy G, Green A, Ellis I, Gelmon K, Turashvili G, Leung S, Aparicio S, Huntsman D, Caldas C, Pharoah P (2010) BCL2 in breast cancer: a favourable prognostic markeracross molecular subtypes and independent of adjuvant therapy received.Br J Cancer 103: 668-675.
16. Diab S, Elledge R, Clark G (2000) Tumor characteristics and clinicaloutcome of elderly women with breast cancer. J Natl Cancer Inst 92 (7) :550-556.
17. Durbecq V, Ameye L, Veys I, Paesmans M, Desmedt C, Sirtaine N, Sotiriou C, Bernard-Marty C, Nogaret J, Piccart M, Larsimont D (2008) A significantproportion of elderly patients develop hormone-dependant "luminal-B" tumoursassociated with aggressive characteristics. Crit Rev Oncol Hematol 67 (1) : 80-92.
18. Elston C, Ellis I (1991) Pathological prognostic factors in breast cancer. I. Thevalue of histological grade in breast cancer: experience from a large studywith long-term follow-up. Histopathology 19 (5) : 403-410.
19. Eppenberger-Castori S, Moore D, Thor A, Edgerton S, KeungW, Eppenberger U, Benz C (2002) Age-associated biomarker profiles of human breast cancer.Int J Biochem Cell Biol 34: 1318-1330.
20. Fleming S, Rastogi A, Dmitrienko A, Johnson K (1999) A comprehensiveprognostic index to predict survival based on multiple comorbidities: afocus on breast cancer. Med Care 37 (6) : 601-614.
21. Gilewski T, Adluri S, Ragupathi G, Zhang S, Yao TJ, Panageas K, Moynahan M, Houghton A, Norton L, Livingston PO (2000) Vaccination of high-riskbreast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyaninconjugate plus QS-21. Clin Cancer Res 6 (5) : 1693-1701.
22. Hanson J, BroweIl D, Cunliffe W, Varma J, Allen A, Hemming D, Shenton B, Young J, Higgs M, Brotherick I, Pearson J (2001) MUC1 expression inprimary breast cancer: the effect of tamoxifen treatment. Breast Cancer ResTreat 67 (3) : 215-222.
23. Haybittle J, Blamey R, Elston C, Johnson J, Doyle P, Campbell F, Nicholson R, Griffiths K (1982) A prognostic index in primary breast cancer. Br JCancer 45 (3) : 361-366.
24. Howell A, Barnes DM, Harland RN, Redford J, Bramwell VH, Wilkinson MJ, Swindell R, Crowther D, Sellwood RA (1984) Steroid-hormone receptorsand survival after first relapse in breast cancer. Lancet 1 (8377) : 588-591.
25. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M (2009) Cancer statistics, 2009. CA Cancer J Clin 59 (4) : 225-249.
26. Kim J, Hwang T, Kang S, Lee S, Bae Y (2009) Prognostic significance of basalmarkers in triple-negative breast cancers. J Breast Cancer 4-13.
27. Kim Y, Won Y, Park K, Song B, Kim J, Oh S, Jeon H, Jung S, Park W (2008) Prognostic significance of HER2 gene amplification according to stage ofbreast cancer. J Korean Med Sci 23 (3) : 414-420
28. Knoop A, Bentzen S, Nielsen M, Rasmussen B, Rose C (2001) Value ofepidermal growth factor receptor, HER2, p53, and steroid receptors inpredicting the efficacy of tamoxifen in high-risk postmenopausal breastcancer patients. J Clin Oncol 19 (14) : 3376-3384.
29. Lee K, Kim J, Jung J, Park J, Park H (2010) Clinicopathological feature andrecurrence pattern of triple negative breast cancer. J Korean Surg Soc 14-19.
30. Linderholm B, Bergqvist J, Hellborg H, Johansson U, Linderholm M, vonSchoultz E, Elmberger G, Skoog L, Bergh J (2009) Shorter survival- timesfollowing adjuvant endocrine therapy in oestrogen-and progesteronereceptorpositive breast cancer overexpressing HER2 and/or with anincreased expression of vascular endothelial growth factor. Med Oncol26 (4) : 480-490.
31. Livasy C, Karaca G, Nanda R, Tretiakova M, Olopade O, Moore D, Perou C (2006) Phenotypic evaluation of the basal-like subtype of invasive breastcarcinoma. Modern Pathol 19 (2) : 264-271.
32. Ma C, Zhou Q, Nie X, Liu G, Di G, Wu J, Lu J, Yang W, Chen J, Shao Z, Shen K, Shen Z (2009) Breast cancer in Chinese elderly women: pathological andclinical characteristics and factors influencing treatment patterns. Crit RevOncol Hematol 71 (3) : 258-265.
33. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Anton A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K, Extra J (2005) Randomized phase II trial ofthe efficacy and safety of trastuzumab combined with docetaxel in patientswith human epidermal growth factor receptor 2-positive metastatic breastcancer administered as first-line treatment: The M77001 study group.J Clin Oncol 23: 4265-4274.
34. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM.Diagnostics SSotN-EWGoC (2005) Reporting recommendations fortumor marker prognostic studies. J Clin Oncol 23 (36) : 9067-9072.
35. Nielson T, hsu F, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, dressler L, Aksan L, Ragaz J, Gown A, Gilks C, Rijn M, Perou C (2004) Immunohistochemical and clinical characterization of thebasal-like subtype of invasive breast carcinoma. Clin Cancer Res 10:5367-5374.
36. O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki A, Koziner B, Chanan-Khan AA, Seymour JF, Bociek RG, Pavletic S, Rai KR (2007) Randomizedphase III trial of fludarabine plus cyclophosphamide with or withoutoblimersen sodium (Bcl-2 antisense) in patients with relapsed orrefractory chronic lymphocytic leukemia. J Clin Oncol 25 (9) : 1114-1120.
37. office: London Office for National Statistics (2006) Cancer Statistics Registration. HerMajesty's stationary office London.
38. Pappo I, Karni T, Sandbank J, Dinur I, Sella A, Stahl-Kent V, Wasserman I, Halevy A (2007) Breast cancer in elderly: histological, hormonal andsurgical characteristics. Breast 16: 60-67.
39. Rakha E, Boyce R, Abd El-Rehim D, Kurien T, Green A, Paish E, Robertson J, Ellis I (2005) Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breastcancer. Mod Pathol 18: 1295-1304.
40. Rakha E, El-Sheikh S, Kandil M, El-Sayed M, Green A, Ellis I (2008) Expression of BRCAI protein in breast cancer and its prognosticsignificance. Hum Pathol 39 (6) : 857-865.
41. Romond E, Perez E, Bryant J, Suman V, Geyer C, Davidson N, Tan-Chiu E, Martino S, Paik S, Kaufman P, Swain S, Pisansky T, Fehrenbacher L, Kutteh L, Vogel V, Visscher D, Yothers G, Jenkins R, Brown A, Dakhil S, Mamounas E, Lingle W, Klein P, Ingle J, Wolmark N (2005) Trastuzumabplus adjuvant chemotherapy for operable HER2-positive breast cancer.N Eng J Med 353 (16) : 1673-1684.
42. Soria D, Garibaldi J, Ambrogi F, Green A, Powe D, Rakha E, Macmillan R, Blamey R, Ball G, Lisboa P, Etchells T, Boracchi P, Biganzoli E, Ellis I (2010) A methodology to identify consensus classes from clusteringalgorithms applied to immunohistochemical data from breast cancerpatients. Comp Biol Med 40 (3) : 318-330.
43. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron J, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou C, Lønning P, Brown P, Børresen-Dale A, Botstein D (2003) Repeated observation of breast tumor subtypesin independent gene expression data sets. Proc Natl Acad Sci USA 100 (14) :8418-8423.
44. Sotiriou C, Neo S, McShane L, Korn E, Long P, Jazaeri A, Martiat P, Fox S, Harris A, Liu E (2003) Breast cancer classification and prognosis based ongene expression profiles from a population-based study. Proc Natl AcadSci USA 100 (18) : 10393-10398.
45. Syed B, Johnston S, Wong D, Green A, Winterbottom L, Kennedy H, SimpsonN, Morgan D, Ellis I, Cheung K (2011a) Long-term (37 years) clinicaloutcome of older women with early operable primary breast cancermanaged in a dedicated clinic. Ann Oncol 23 (6) : 1465-1471.
46. Syed B, Leonard R, Ellis I, Cheung K (2011b) HER2 positive primary breastcancer in older women: clinical significance and therapeutic challenge.In HER2 and Cancer: Mechanism, Testing and Targeted Therapy, Williams SI, Rogers CE (eds) Vol. 1, Chapter 5pp 123-143. NovaPublishers: New York.
47. Tan D, Marchio C, Jones R, Savage K, Smith I, Dowsett M, Reis J (2008) Triplenegative breast cancer: molecular profiling and prognostic impact inadjuvant anthracycline-treated patients. Breast Cancer Res Treat 111 (1) :27-44.
48. Tse G, Tan P, Lau K, de Andrade V, Lui P, Vong J, Chaiwun B, Lam C, Yu A, Moriya T (2009) Breast cancer in the elderly: a histological assessment.Histopathology 55 (4) : 441-451.
49. Tsutsui S, Ohno S, Murakami S, Hachitanda Y, Oda S (2002) Prognostic valueof c-erbB2 expression in breast cancer. J Surg Oncol 79 (4) : 216-223.
50. Vallejos C, Gómez H, Cruz W, Pinto J, Dyer R, Velarde R, Suazo J, Neciosup S, León M, de la Cruz M, Vigil C (2010) Breast cancer classificationaccording to immunohistochemistry markers: subtypes and associationwith clinicopathologic variables in a peruvian hospital database. ClinBreast Cancer 10 (4) : 294-300.
51. van der Vegt B, de Roos M, Peterse J, Patriarca C, Hilkens J, de Bock G, Wesseling J (2007) The expression pattern of MUC1 (EMA) is related totumour characteristics and clinical outcome of invasive ductal breastcarcinoma. Histopathology 51 (3) : 322-335.
52. Viani G, Afonso S, Stefano E, De Fendi L, Soares F (2007) Adjuvanttrastuzumab in the treatment of her-2-positive early breast cancer: a metaanalysisof published randomized trials. Biomed Central Cancer 7: 153.
53. Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW (2001) Effect of age and comorbidity in postmenopausal breast cancer patientsaged 55 years and older. J Am Med Assoc 285 (7) : 885-892.